Emerging from the UK, retatrutide, a novel compound , is creating considerable excitement within the medical community regarding its promise for physique regulation. This dual GIP and GLP-1 target agonist appears to deliver a considerable advantage over current therapies, showing encouraging results in preliminary clinical trials . Researchers beli